Conatus Pharma Reports Acceptance of Abstracts for EASL Meeting

Conatus Pharmaceuticals Inc.

announced today the acceptance of two abstracts for presentation at The International Liver Congress™ 2016, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Barcelona, Spain, April 13-17, 2016. An abstract detailing results from the three-month, double-blind, placebo-controlled stage of the company's multicenter Phase 2 Liver Cirrhosis clinical trial of emricasan, the company's first-in-class, orally active pan-caspase protease inhibitor, was accepted for a late breaker oral presentation. The oral presentation (#LBO5) entitled, "Emricasan (IDN-6556) orally for three months in patients with cirrhosis and MELD scores 11-18 improves clinical parameters of cirrhosis in patients with baseline MELD score ≥15," will be delivered on Saturday, April 16, at 5:00 p.m. CET, by Catherine Frenette, M.D., Medical Director of Liver Transplantation at Scripps Clinic, La Jolla, CA, and a principal investigator in the Liver Cirrhosis trial. An abstract addressing preclinical results in ex vivo cell culture and in vivo mouse models of hepatocellular carcinoma with IDN-7314, an orally active pan-caspase inhibitor closely related to emricasan, was accepted for presentation as a poster. The abstract was published today on the EASL website at http://ilc-congress.eu/abstracts/. The poster (#FRI-078) entitled, "The potent pan-caspase inhibitor IDN-7314 does not affect tumor growth rate nor does it antagonize the efficacy of sorafenib in models of hepatocellular carcinoma," will be displayed on Friday, April 15, from 8:00 a.m. to 6:00 p.m. CET, and will be attended by presenting author Patricia C. Contreras, Ph.D., Vice President, Preclinical Development at Conatus and lead author on the poster, during a scheduled poster session.